top of page

Gilead's Dan O'Day on 1Q23 Earnings

  • Apr 27, 2023
  • 1 min read

Updated: Jun 16, 2023

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.



Brad Loncar visited Gilead Science's headquarters in Foster City, California and had the opportunity to interview Chairman and CEO Dan O'Day about Gilead’s business.


Discussed:


- Gilead’s transformation into oncology and other areas.

- The business model of cell therapy.

- The competitive landscape for the ADC medicine Trodelvy.

- Other oncology targets like CD47 and TIGIT.

- Long-acting medicines for HIV.

- What it was like to develop remdesivir during the pandemic.

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page